• +1-646-491-9876
    • +91-20-67278686

    Search

    Liver Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2017

    Liver Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2017

    • Report Code ID: RW0001985401
    • Category Life Sciences
    • No. of Pages 136
    • Publication Month Aug-17
    • Publisher Name GlobalData
    Liver Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2017

    Summary

    GlobalData's Medical Devices sector report, "Liver Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2017" provides an overview of Liver Cancer Diagnostic Tests currently in pipeline stage.

    The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Cancer Diagnostic Tests pipeline products.

    This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

    -Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

    Scope

    -Extensive coverage of the Liver Cancer Diagnostic Tests under development
    -The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
    -The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects
    -The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
    -The report provides key clinical trial data of ongoing trials specific to pipeline products
    -Recent developments in the segment / industry

    Reasons to buy

    The report enables you to-
    -Formulate significant competitor information, analysis, and insights to improve R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    -Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development
    -Develop market-entry and market expansion strategies
    -Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
    -In-depth analysis of the product's current stage of development, territory and estimated launch date
    Table of Contents
    1. Table of Contents 2
    1.1 List of Tables 5
    1.2 List of Figures 7
    2 Introduction 8
    2.1 Liver Cancer Diagnostic Tests Overview 8
    3 Products under Development 9
    3.1 Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 9
    3.2 Liver Cancer Diagnostic Tests-Pipeline Products by Territory 10
    3.3 Liver Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 11
    3.4 Liver Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 12
    4 Liver Cancer Diagnostic Tests-Pipeline Products under Development by Companies 13
    4.1 Liver Cancer Diagnostic Tests Companies-Pipeline Products by Stage of Development 13
    4.2 Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 15
    5 Liver Cancer Diagnostic Tests Companies and Product Overview 17
    5.1 Abbott Diagnostics Company Overview 17
    5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 17
    5.2 Abcodia Ltd Company Overview 22
    5.2.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
    5.3 AXO Science SAS Company Overview 23
    5.3.1 AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 23
    5.4 BioMark Technologies Inc Company Overview 26
    5.4.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 26
    5.5 Bioprognos SL Company Overview 27
    5.5.1 Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 27
    5.6 China Sky One Medical Inc Company Overview 28
    5.6.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 28
    5.7 Digna Biotech SL Company Overview 29
    5.7.1 Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 29
    5.8 Drexel University Company Overview 31
    5.8.1 Drexel University Pipeline Products & Ongoing Clinical Trials Overview 31
    5.9 Exact Sciences Corp Company Overview 33
    5.9.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 33
    5.10 German Cancer Research Center Company Overview 34
    5.10.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 34
    5.11 Glycotest Inc Company Overview 35
    5.11.1 Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview 35
    5.12 ImCare Biotech LLC Company Overview 36
    5.12.1 ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview 36
    5.13 Imperial College London Company Overview 37
    5.13.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 37
    5.14 IntegraGen SA Company Overview 38
    5.14.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 38
    5.15 Matrix-Bio, Inc. Company Overview 39
    5.15.1 Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
    5.16 NanoString Technologies Inc Company Overview 41
    5.16.1 NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 41
    5.17 National Cancer Institute US Company Overview 42
    5.17.1 National Cancer Institute US Pipeline Products & Ongoing Clinical Trials Overview 42
    5.18 Oncimmune (USA) LLC Company Overview 44
    5.18.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 44
    5.19 Orion Genomics LLC Company Overview 45
    5.19.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45
    5.20 PleX Diagnostics Inc (Inactive) Company Overview 46
    5.20.1 PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 46
    5.21 ProMIS Neurosciences Inc Company Overview 47
    5.21.1 ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 47
    5.22 Proplex Technologies Llc Company Overview 48
    5.22.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 48
    5.23 Proteome Sciences Plc Company Overview 49
    5.23.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 49
    5.24 Roche Diagnostics International Ltd Company Overview 50
    5.24.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
    5.25 University of Rochester Company Overview 52
    5.25.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 52
    5.26 Ventana Medical Systems Inc Company Overview 53
    5.26.1 Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 53
    5.27 Viomics Inc. Company Overview 54
    5.27.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
    5.28 XEPTAGEN SpA Company Overview 55
    5.28.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 55
    5.29 Xiamen Zeesan Biotech Co.,Ltd Company Overview 60
    5.29.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
    6 Liver Cancer Diagnostic Tests-Recent Developments 61
    6.1 Jul 25, 2017: Proteome Sciences: Interim Results for the Six Months Ended 30 June 2017 61
    6.2 Jul 11, 2017: Integragen Reports Continued Growth During 1st Half Of 2017 61
    6.3 Jul 10, 2017: Trovagene Regains Compliance with NASDAQ Listing Requirements 62
    6.4 Jul 10, 2017: ProMIS Neurosciences Provides Second Quarter Update for 2017 62
    6.5 Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri 63
    6.6 Jun 27, 2017: Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri 64
    6.7 Jun 12, 2017: Proteome Sciences: New Registered Address 65
    6.8 Jun 06, 2017: ProMIS Neurosciences Appoints William C. Mobley to Scientific Advisory Board 65
    6.9 May 10, 2017: Trovagene Announces First Quarter 2017 Company Highlights and Financial Results 66
    6.10 May 10, 2017: NanoString Appoints Elisha W. Finney to Board of Directors 67
    6.11 May 09, 2017: ProMIS Neurosciences Announces Q1 2017 Quarterly Results 68
    6.12 May 04, 2017: PerkinElmer Announces Financial Results for the First Quarter of 2017 69
    6.13 May 04, 2017: NanoString Technologies Releases Operating Results for First Quarter of 2017 70
    6.14 May 03, 2017: Blueprint Medicines Reports First Quarter 2017 Financial Results 71
    6.15 May 02, 2017: Pfizer Reports First-Quarter 2017 Results 72
    6.16 Apr 21, 2017: IntegraGen Announces 2016 Annual Results: Increase in operating revenues and significant improvement in operating income (+22%) 77
    6.17 Apr 13, 2017: Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board 80
    6.18 Apr 03, 2017: Proteome Sciences Announces Appointment of Richard Dennis as Chief Commercial Officer 81
    6.19 Mar 30, 2017: ProMIS Neurosciences announces overview of first quarter 2017 progress and outlook for near term value creation 82
    6.20 Mar 28, 2017: Proteome Sciences Announces Preliminary results for the year ended 31 December 2016 Notice of AGM 82
    6.21 Mar 23, 2017: PerkinElmer to Display Portfolio of Cancer Research Technologies and Workflow Solutions at 2017 AACR Annual Meeting 91
    6.22 Mar 22, 2017: ProMIS Neurosciences Announces Appointment of Daniel Geffken as Chief Financial Officer 93
    6.23 Mar 15, 2017: Trovagene Reports Fourth Quarter and Year End 2016 Financial Results 93
    6.24 Mar 15, 2017: ProMIS Neurosciences Announces Fiscal 2016 Annual Results 94
    6.25 Mar 09, 2017: Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results 96
    6.26 Mar 02, 2017: ProMIS Neurosciences announces appointment of Anthony Giovinazzo to its Board of Directors 98
    6.27 Mar 01, 2017: NanoString Technologies Releases Fourth Quarter and Full Year 2016 Operating Results and Provides 2017 Outlook 99
    6.28 Feb 27, 2017: The Novartis Institutes for BioMedical Research and NanoString Technologies Demonstrates at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 100
    6.29 Feb 23, 2017: Ronald E. Blaylock Elected to Pfizer's Board of Directors 101
    6.30 Feb 02, 2017: PerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2016 101
    6.31 Jan 31, 2017: Pfizer Reports Fourth-Quarter And Full-Year 2016 Results 103
    6.32 Jan 10, 2017: NanoString Technologies Provides Preliminary Operational and Financial Results for 2016 109
    6.33 Jan 09, 2017: IntegraGen Reports Sharp Increase in Sales During 2016 110
    6.34 Nov 21, 2016: Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire 110
    6.35 Nov 14, 2016: Blueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the Transition of Christoph Lengauer, Ph.D., MBA, to a Newly Created Executive Vice President Role 111
    6.36 Nov 10, 2016: Blueprint Medicines Reports Third Quarter 2016 Financial Results 112
    6.37 Nov 09, 2016: Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments 113
    6.38 Nov 07, 2016: PerkinElmer Announces Financial Results for the Third Quarter of 2016 115
    6.39 Nov 02, 2016: ProMIS Neurosciences Announces Third Quarter 2016 Results 116
    6.40 Nov 02, 2016: NanoString Technologies Releases Operating Results for Third Quarter of 2016 117
    6.41 Nov 01, 2016: Pfizer Reports Third-Quarter 2016 Results 118
    6.42 Oct 18, 2016: ProMIS Neurosciences announces appointment of Dr. Richard Gregory to its Board of Directors 124
    6.43 Oct 17, 2016: PerkinElmer Elects Samuel Chapin to Board of Directors 124
    6.44 Oct 14, 2016: IntegraGen Reports Revenues for First Half of 2016 125
    6.45 Sep 26, 2016: Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation 126
    6.46 Sep 26, 2016: PerkinElmer Announces New Organizational Structure 127
    6.47 Sep 15, 2016: Proteome Sciences: Interim Results 128
    6.48 Sep 07, 2016: Pfizer Appoints Chief Scientific Officer for Neuroscience Research 128
    6.49 Sep 06, 2016: Blueprint Medicines Announces Appointment of Tracey McCain as Chief Legal Officer and Executive Vice President 129
    6.50 Aug 12, 2016: ProMIS Neurosciences Announces Second Quarter 2016 Results 129
    6.51 Aug 09, 2016: Blueprint Medicines Reports Second Quarter 2016 Financial Results 131
    7 Appendix 133
    7.1 Methodology 133
    7.2 About GlobalData 136
    7.3 Contact Us 136
    7.4 Disclaimer 136

    List of Tables
    Table 1: Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 9
    Table 2: Liver Cancer Diagnostic Tests-Pipeline Products by Territory 10
    Table 3: Liver Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 11
    Table 4: Liver Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 12
    Table 5: Liver Cancer Diagnostic Tests Companies-Pipeline Products by Stage of Development 13
    Table 6: Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 15
    Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 17
    Table 8: ARCHITECT c16000 System-PIVKA Assay-Product Status 17
    Table 9: ARCHITECT c16000 System-PIVKA Assay-Product Description 18
    Table 10: ARCHITECT c4000 System-PIVKA Assay-Product Status 18
    Table 11: ARCHITECT c4000 System-PIVKA Assay-Product Description 18
    Table 12: ARCHITECT c8000 System-PIVKA Assay-Product Status 19
    Table 13: ARCHITECT c8000 System-PIVKA Assay-Product Description 19
    Table 14: ARCHITECT ci16200 Integrated System-PIVKA Assay-Product Status 19
    Table 15: ARCHITECT ci16200 Integrated System-PIVKA Assay-Product Description 20
    Table 16: ARCHITECT ci4100 Integrated System-PIVKA Assay-Product Status 20
    Table 17: ARCHITECT ci4100 Integrated System-PIVKA Assay-Product Description 20
    Table 18: ARCHITECT ci8200 Integrated System-PIVKA Assay-Product Status 21
    Table 19: ARCHITECT ci8200 Integrated System-PIVKA Assay-Product Description 21
    Table 20: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
    Table 21: Biomarker Test-Liver Cancer-Product Status 22
    Table 22: Biomarker Test-Liver Cancer-Product Description 22
    Table 23: AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 23
    Table 24: Multiplexed Detection-Des-Carboxy Prothrombin-Product Status 23
    Table 25: Multiplexed Detection-Des-Carboxy Prothrombin-Product Description 23
    Table 26: Multiplexed Detection-Matrix metalloproteinase 1-Product Status 24
    Table 27: Multiplexed Detection-Matrix metalloproteinase 1-Product Description 24
    Table 28: Multiplexed Detection-Procollagen type III N-terminal peptide-Product Status 24
    Table 29: Multiplexed Detection-Procollagen type III N-terminal peptide-Product Description 25
    Table 30: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 26
    Table 31: Biomarker Assay-Hepatocellular Cancer-Product Status 26
    Table 32: Biomarker Assay-Hepatocellular Cancer-Product Description 26
    Table 33: Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 27
    Table 34: MBDAA Liver Cancer Test-Product Status 27
    Table 35: MBDAA Liver Cancer Test-Product Description 27
    Table 36: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 28
    Table 37: Diagnostic Kit-Liver Cancer-Product Status 28
    Table 38: Diagnostic Kit-Liver Cancer-Product Description 28
    Table 39: Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 29
    Table 40: HCC Molecular Marker Assay-Product Status 29
    Table 41: HCC Molecular Marker Assay-Product Description 29
    Table 42: Oxidated APO-A1 Assay-Product Status 30
    Table 43: Oxidated APO-A1 Assay-Product Description 30
    Table 44: Drexel University Pipeline Products & Ongoing Clinical Trials Overview 31
    Table 45: Diagnostic Test-Liver Cancer-Product Status 31
    Table 46: Diagnostic Test-Liver Cancer-Product Description 31
    Table 47: Glycan-Based Biomarker Assay-Liver Cancer-Product Status 32
    Table 48: Glycan-Based Biomarker Assay-Liver Cancer-Product Description 32
    Table 49: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 33
    Table 50: Blood-based Liver Cancer Test-Product Status 33
    Table 51: Blood-based Liver Cancer Test-Product Description 33
    Table 52: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 34
    Table 53: RAGE Based Diagnostic Assay-Liver Cancer-Product Status 34
    Table 54: RAGE Based Diagnostic Assay-Liver Cancer-Product Description 34
    Table 55: Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview 35
    Table 56: HCC Panel-Product Status 35
    Table 57: HCC Panel-Product Description 35
    Table 58: ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview 36
    Table 59: HepatoDetect Diagnostic Kit-Product Status 36
    Table 60: HepatoDetect Diagnostic Kit-Product Description 36
    Table 61: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 37
    Table 62: Diagnostic Assay-HCC-Product Status 37
    Table 63: Diagnostic Assay-HCC-Product Description 37
    Table 64: IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 38
    Table 65: Diagnostic Test-Hepatocellular Carcinoma-Product Status 38
    Table 66: Diagnostic Test-Hepatocellular Carcinoma-Product Description 38
    Table 67: Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
    Table 68: VeraMarker LCS (Liver Cancer Screening) Test-Product Status 39
    Table 69: VeraMarker LCS (Liver Cancer Screening) Test-Product Description 39
    Table 70: VeraMarker Liver Cancer Screening Test-Hepatitis-Product Status 40
    Table 71: VeraMarker Liver Cancer Screening Test-Hepatitis-Product Description 40
    Table 72: NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 41
    Table 73: In Vitro Diagnostic Assay-HCC Gene Signature-Product Status 41
    Table 74: In Vitro Diagnostic Assay-HCC Gene Signature-Product Description 41
    Table 75: National Cancer Institute US Pipeline Products & Ongoing Clinical Trials Overview 42
    Table 76: HCC Gene Signature Diagnostic Test-Product Status 42
    Table 77: HCC Gene Signature Diagnostic Test-Product Description 42
    Table 78: HCC Gene Signature Prognostic Test-Product Status 43
    Table 79: HCC Gene Signature Prognostic Test-Product Description 43
    Table 80: Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 44
    Table 81: EarlyCDT-Liver Cancer-Product Status 44
    Table 82: EarlyCDT-Liver Cancer-Product Description 44
    Table 83: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45
    Table 84: Diagnostic Assay-Liver Cancer-Product Status 45
    Table 85: Diagnostic Assay-Liver Cancer-Product Description 45
    Table 86: PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 46
    Table 87: HCCpleX-Product Status 46
    Table 88: HCCpleX-Product Description 46
    Table 89: ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 47
    Table 90: Screening Test-Liver Cancer-Product Status 47
    Table 91: Screening Test-Liver Cancer-Product Description 47
    Table 92: Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 48
    Table 93: Biomarker Diagnostic Test-Liver Cancer-Product Status 48
    Table 94: Biomarker Diagnostic Test-Liver Cancer-Product Description 48
    Table 95: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 49
    Table 96: Biomarker Assay-Liver Cancer-Product Status 49
    Table 97: Biomarker Assay-Liver Cancer-Product Description 49
    Table 98: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
    Table 99: Cobas 8000 Analyzer Series With e 801 Module-PIVKA Assay-Product Status 50
    Table 100: Cobas 8000 Analyzer Series With e 801 Module-PIVKA Assay-Product Description 50
    Table 101: Glypican-3 MAb Companion Diagnostic Test-Product Status 51
    Table 102: Glypican-3 MAb Companion Diagnostic Test-Product Description 51
    Table 103: University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 52
    Table 104: Biomarker Test-HCC-Product Status 52
    Table 105: Biomarker Test-HCC-Product Description 52
    Table 106: Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 53
    Table 107: BLU-554 Companion Diagnostic Assay-Hepatocellular Carcinoma-Product Status 53
    Table 108: BLU-554 Companion Diagnostic Assay-Hepatocellular Carcinoma-Product Description 53
    Table 109: Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
    Table 110: Diagnostic Assay-Liver Cancer-Product Status 54
    Table 111: Diagnostic Assay-Liver Cancer-Product Description 54
    Table 112: XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 55
    Table 113: compleXima HCC Biochip-Liver Cancer-Product Status 55
    Table 114: compleXima HCC Biochip-Liver Cancer-Product Description 55
    Table 115: DCP-IgM Kit-Liver Cancer-Product Status 56
    Table 116: DCP-IgM Kit-Liver Cancer-Product Description 56
    Table 117: GPC3-IgM Kit-Liver Cancer-Product Status 56
    Table 118: GPC3-IgM Kit-Liver Cancer-Product Description 57
    Table 119: Osteopontin-IgM Kit-Liver Cancer-Product Status 57
    Table 120: Osteopontin-IgM Kit-Liver Cancer-Product Description 57
    Table 121: Survivin-IgM Kit-Liver Cancer-Product Status 58
    Table 122: Survivin-IgM Kit-Liver Cancer-Product Description 58
    Table 123: VEGF-IgM Kit-Liver Cancer-Product Status 58
    Table 124: VEGF-IgM Kit-Liver Cancer-Product Description 59
    Table 125: Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
    Table 126: Theranostic-Liver Cancer Metastasis-Product Status 60
    Table 127: Theranostic-Liver Cancer Metastasis-Product Description 60
    Table 128: Glossary 135

    List of Figures
    Figure 1: Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 9
    Figure 2: Liver Cancer Diagnostic Tests-Pipeline Products by Territory 10
    Figure 3: Liver Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 11
    Figure 4: Liver Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 12
    Abbott Diagnostics
    Abcodia Ltd
    AXO Science SAS
    BioMark Technologies Inc
    Bioprognos SL
    China Sky One Medical Inc
    Digna Biotech SL
    Drexel University
    Exact Sciences Corp
    German Cancer Research Center
    Glycotest Inc
    ImCare Biotech LLC
    Imperial College London
    IntegraGen SA
    Matrix-Bio, Inc.
    NanoString Technologies Inc
    National Cancer Institute US
    Oncimmune (USA) LLC
    Orion Genomics LLC
    PleX Diagnostics Inc
    ProMIS Neurosciences Inc
    Proplex Technologies Llc
    Proteome Sciences Plc
    Roche Diagnostics International Ltd
    University of Rochester
    Ventana Medical Systems Inc
    Viomics Inc.
    XEPTAGEN SpA
    Xiamen Zeesan Biotech Co.,Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//liver-cancer-diagnostic-tests-medical-devices-pipeline-assessment-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//liver-cancer-diagnostic-tests-medical-devices-pipeline-assessment-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//liver-cancer-diagnostic-tests-medical-devices-pipeline-assessment-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments